Lung cancer gene therapy trial halted early
NCT ID NCT05062980
First seen Jun 07, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This early-stage trial tested a new gene therapy called quaratusugene ozeplasmid (Reqorsa) combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced non-small cell lung cancer who had already received treatment. The goal was to see if the combination was safe and could shrink tumors. However, the study was stopped early because not enough people enrolled, so only 5 participants were treated and the second phase never started.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Millennium Oncology
Houston, Texas, 77090, United States
-
Moffitt Cancer Center - Magnolia Campus
Tampa, Florida, 33612, United States
-
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121, United States
-
The Valley Hospital - Luckow Pavilion
Paramus, New Jersey, 07652, United States
-
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
quaratusugene ozeplasmid (Reqorsa) combined with pembrolizumab
What this could lead to
If successful, this could point toward a new gene therapy option for lung cancer patients who have already tried other treatments.
What could go wrong
The trial was terminated early due to slow enrollment, so results are very limited. It was only in phase 1, testing safety and dosing, so it is far from proving effectiveness.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.